Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00777062 · ClinicalTrials.gov registry record · Phase 2
VIVITROL as a Treatment for Cocaine and Alcohol Dependence
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00777062: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT00777062 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00777062, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
To evaluate the efficacy of VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of co-occurring cocaine and alcohol dependence
Interventions
- DRUG Placebo
- DRUG VIVITROL (Naltrexone extended-release injectable suspension)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2009-07 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00777062
The ClinicalTrials.gov registry entry for NCT00777062 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00777062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00777062 about?
NCT00777062 is a clinical study titled "VIVITROL as a Treatment for Cocaine and Alcohol Dependence". To evaluate the efficacy of VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of co-occurring cocaine and alcohol dependence
What is the current status of trial NCT00777062?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2009-07. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00777062?
The interventions under investigation include: Placebo (DRUG), VIVITROL (Naltrexone extended-release injectable suspension) (DRUG).
Who is sponsoring clinical trial NCT00777062?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.